372 related articles for article (PubMed ID: 19800951)
41. Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13)NH(2), [(3)H]nociceptin/orphaninFQ(1-17)OH and [(125)I]Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors.
Hashiba E; Lambert DG; Farkas J; Toth G; Smith G
Neurosci Lett; 2002 Aug; 328(1):5-8. PubMed ID: 12123846
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt
Cerlesi MC; Ding H; Bird MF; Kiguchi N; Ferrari F; Malfacini D; Rizzi A; Ruzza C; Lambert DG; Ko MC; Calo G; Guerrini R
Eur J Pharmacol; 2017 Jan; 794():115-126. PubMed ID: 27871910
[TBL] [Abstract][Full Text] [Related]
43. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.
Rizzi A; Malfacini D; Cerlesi MC; Ruzza C; Marzola E; Bird MF; Rowbotham DJ; Salvadori S; Guerrini R; Lambert DG; Calo G
Br J Pharmacol; 2014 Sep; 171(17):4138-53. PubMed ID: 24903280
[TBL] [Abstract][Full Text] [Related]
45. Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ.
Berger H; Albrecht E; Wallukat G; Bienert M
Br J Pharmacol; 1999 Feb; 126(3):555-8. PubMed ID: 10188961
[TBL] [Abstract][Full Text] [Related]
46. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
47. Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system.
Wainford RD; Kapusta DR
Am J Physiol Regul Integr Comp Physiol; 2009 Feb; 296(2):R280-8. PubMed ID: 18987291
[TBL] [Abstract][Full Text] [Related]
48. Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.
Kapusta DR; Burmeister MA; Calo' G; Guerrini R; Gottlieb HB; Kenigs VA
J Pharmacol Exp Ther; 2005 Aug; 314(2):643-51. PubMed ID: 15855356
[TBL] [Abstract][Full Text] [Related]
49. Species differences in the efficacy of compounds at the nociceptin receptor (ORL1).
Burnside JL; Rodriguez L; Toll L
Peptides; 2000 Jul; 21(7):1147-54. PubMed ID: 10998550
[TBL] [Abstract][Full Text] [Related]
50. Antitussive profile of the NOP agonist Ro-64-6198 in the guinea pig.
McLeod RL; Jia Y; Fernandez X; Parra LE; Wang X; Tulshian DB; Kiselgof EJ; Tan Z; Fawzi AB; Smith-Torhan A; Zhang H; Hey JA
Pharmacology; 2004 Jul; 71(3):143-9. PubMed ID: 15161996
[TBL] [Abstract][Full Text] [Related]
51. The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.
Brookes ZL; Stedman EN; Brown NJ; Hebbes CP; Guerrini R; Calo G; Reilly CS; Lambert DG
PLoS One; 2013; 8(9):e74943. PubMed ID: 24086402
[TBL] [Abstract][Full Text] [Related]
52. Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices.
Kuo CJ; Liao YY; Guerrini R; Calo' G; Chiou LC
Eur J Pharmacol; 2008 Jan; 579(1-3):110-5. PubMed ID: 17976580
[TBL] [Abstract][Full Text] [Related]
53. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat.
Economidou D; Hansson AC; Weiss F; Terasmaa A; Sommer WH; Cippitelli A; Fedeli A; Martin-Fardon R; Massi M; Ciccocioppo R; Heilig M
Biol Psychiatry; 2008 Aug; 64(3):211-8. PubMed ID: 18367152
[TBL] [Abstract][Full Text] [Related]
54. The effects of [Arg14, Lys15] nociceptin/orphanin FQ, a highly potent agonist of the NOP receptor, on in vitro and in vivo gastrointestinal functions.
Broccardo M; Linari G; Guerrini R; Agostini S; Petrella C; Improta G
Peptides; 2005 Sep; 26(9):1590-7. PubMed ID: 16112397
[TBL] [Abstract][Full Text] [Related]
55. Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.
Barnes TA; McDonald J; Rowbotham DJ; Duarte TL; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2007 Nov; 376(3):217-25. PubMed ID: 17899014
[TBL] [Abstract][Full Text] [Related]
56. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist.
Bigoni R; Calo' G; Rizzi A; Guerrini R; De Risi C; Hashimoto Y; Hashiba E; Lambert DG; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):565-8. PubMed ID: 10832612
[TBL] [Abstract][Full Text] [Related]
57. Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
Trapella C; Fischetti C; Pela' M; Lazzari I; Guerrini R; Calo' G; Rizzi A; Camarda V; Lambert DG; McDonald J; Regoli D; Salvadori S
Bioorg Med Chem; 2009 Jul; 17(14):5080-95. PubMed ID: 19527931
[TBL] [Abstract][Full Text] [Related]
58. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
59. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex.
Marti M; Stocchi S; Paganini F; Mela F; De Risi C; Calo' G; Guerrini R; Barnes TA; Lambert DG; Beani L; Bianchi C; Morari M
Br J Pharmacol; 2003 Jan; 138(1):91-8. PubMed ID: 12522077
[TBL] [Abstract][Full Text] [Related]
60. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
Dooley CT; Spaeth CG; Berzetei-Gurske IP; Craymer K; Adapa ID; Brandt SR; Houghten RA; Toll L
J Pharmacol Exp Ther; 1997 Nov; 283(2):735-41. PubMed ID: 9353393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
